Objectives: To identify methylphenidate profiles over several years in a national sample of boys and examine behavioral and sociodemographic predictors of use.
Study Design: Five cycles of a Canadian survey were used, resulting in 1447 boys followed from 2 to 3 years to 10 to 11 years. Mother reports of boys' methylphenidate use from 4 to 5 years to 10 to 11 years were used to identify profiles over time. Mother-reported sociodemographic and child behavior data at 2 to 3 years were then used to predict methylphenidate profiles.
Results: Three methylphenidate profiles were identified: no use (87.2%); slow-rising, intermittent (11.2%); and fast-rising, stable (1.6%). Sociodemographic variables were not significant predictors. Boys with greater hyperactivity-impulsivity, greater inattention, and less disruptive behavior were more likely to belong to the fast-rising, stable methylphenidate profile. Although 13% of boys were using methylphenidate over time, there were 2 heterogeneous profiles. In the first profile, there were very few initial users followed by a steady increase in the number of boys using methylphenidate over time. Among these boys, however, use was inconsistent over time. In the second profile, there was a sharp onset of methylphenidate use on school entry, followed by consistent use thereafter.
Conclusions: These findings have implications for the treatment effectiveness of attention deficit-hyperactivity disorder symptoms. It is important to continue examining the role of disruptive behavior because its co-occurrence with attention deficit-hyperactivity disorder symptoms and methylphenidate use is complex.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpeds.2009.05.028 | DOI Listing |
J Atten Disord
January 2025
University of Amsterdam, The Netherlands.
Objective: Stimulant medications are the primary pharmacological intervention for ADHD, yet our understanding of how sex and gender impact stimulant treatment outcomes remains limited. Clinical guidelines do not differ for female and male individuals despite possible sex and gender-related differences in effectiveness, adverse events, and pharmacokinetics. This theoretical framework identifies five key knowledge gaps relating to sex and gender effects in stimulant treatment.
View Article and Find Full Text PDFCNS Drugs
January 2025
Faculty of Environmental and Life Sciences, Centre for Innovation in Mental Health, School of Psychology, University of Southampton, Southampton, UK.
Background: Raynaud syndrome (RS) is a peripheral vasculopathy characterised be impaired acral perfusion typically manifesting as skin discolouration with pallor, cyanosis and/or erythema, and increased sensitivity to cold. RS may be primary or secondary to systemic disease, lifestyle and environmental factors or medication. RS has been reported with medication to treat ADHD, but we found no recent comprehensive overview of the literature.
View Article and Find Full Text PDFJ Exp Anal Behav
January 2025
Department of Psychology, University of North Carolina Wilmington, Wilmington, NC, USA.
Under rapid-acquisition, concurrent-chains choice procedures, psychomotor stimulants typically decrease the sensitivity of responding to changes in separate dimensions of reinforcement. Across two experiments, pigeons chose between outcomes that differed in terms of reinforcement delay and magnitude (the dimensions involved in delay discounting or "impulsive" choice; Experiment 1) or reinforcement probability and magnitude (the dimensions involved in probability discounting or "risky" choice; Experiment 2). Outcomes associated with each terminal link were varied independently and pseudorandomly across sessions such that in dominated sessions one terminal link was favorable in terms of both dimensions (sooner, larger in Experiment 1 and more likely, larger in Experiment 2) and in trade-off sessions each terminal link was favorable in terms of a different dimension.
View Article and Find Full Text PDFAm J Med Genet B Neuropsychiatr Genet
January 2025
Biruni University Research Center (B@MER), Biruni University, Istanbul, Turkey.
Pharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin-3 (LPHN3), and Catechol-O-methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1, LPHN3, and COMT in the Turkish population. The study included 102 children and adolescents with ADHD, who were categorized as responders, or the adverse effect group based on their treatment response.
View Article and Find Full Text PDFMol Psychiatry
January 2025
Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, 80078, Naples, Italy.
Lysosomal storage disorders characterized by defective heparan sulfate (HS) degradation, such as Mucopolysaccharidosis type IIIA-D (MPS-IIIA-D), result in neurodegeneration and dementia in children. However, dementia is preceded by severe autistic-like behaviours (ALBs), presenting as hyperactivity, stereotypies, social interaction deficits, and sleep disturbances. The absence of experimental studies on ALBs' mechanisms in MPS-III has led clinicians to adopt symptomatic treatments, such as antipsychotics, which are used for non-genetic neuropsychiatric disorders.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!